Zogenix (ZGNX -3.2%) reports preliminary Q4 gross sales of its Sumavel DosePro migraine-relief drug totaled $14M, with unit shipments rising 2.2% Q/Q to 141,780.
Net product revenue totaled $9M. That's officially up from a Q3 level of $6.9M, but the latter figure was affected by a $2.4M increase in Zogenix's estimate for future product returns.
Zogenix says it ended Q4 with $72M in cash/equivalents. Full Q4 results are expected in early March.